Box of Moderna's mRNA flu vaccine, mFLUSIVA, the subject of the FDA approval.FDA Approves mRNA Flu Vaccine Despite RFK Jr.'s Opposition
Intra-Party Split Detected
The FDA, part of RFK Jr.'s HHS, approved the mRNA vaccine despite Kennedy's public criticism of mRNA technology and his department's cancellation of ~$500 million in mRNA vaccine contracts, revealing tension between vaccine-skeptic officials and regulators/scientific advisory panels who unanimously backed the vaccine's approval.
Left says
- •mRNA technology offers faster production timelines than egg-based methods, which could prove critical if a pandemic flu strain emerges and rapid vaccine scaling becomes necessary.
- •The FDA's independent vaccine advisory committee unanimously found the vaccine's benefits outweighed its risks for both age groups, underscoring that scientific review, not political pressure, ultimately guided the outcome.
- •The initial rejection of Moderna's application by then-vaccine chief Vinay Prasad is seen as evidence of a politically hostile environment toward mRNA vaccines under Kennedy's influence at HHS.
- •The approval represents a rebuke of sorts to Kennedy's broader campaign against mRNA platforms, including his cancellation of nearly $500 million in mRNA research contracts, showing that regulatory science can still prevail despite leadership skepticism.
Right says
- •The FDA's about-face after initially refusing to even review the application raises legitimate questions about the consistency and rigor of the agency's standards for comparator trials, especially for older adults.
- •Secretary Kennedy's concerns about mRNA technology reflect a broader push toward diversifying vaccine platforms and redirecting federal funds toward what he considers safer, more established alternatives.
- •The accelerated approval for adults 65 and older, contingent on a future postmarket study, means the vaccine's effectiveness in the most vulnerable age group is not yet fully confirmed.
- •Skepticism toward pharmaceutical companies like Moderna is warranted given past controversies, including allegations that the company withheld data from regulators during its bivalent booster approval process.
Common Take
High Consensus- The FDA approved Moderna's mFlusiva vaccine for adults 50 to 64 through traditional approval and for those 65 and older through accelerated approval pending further study.
- The FDA initially refused to review Moderna's application earlier in the year before reversing course about a week later after the company revised its regulatory approach.
- Influenza remains a serious public health threat, with tens of thousands of Americans dying from the flu annually, particularly among older adults.
- Robert F. Kennedy Jr., as HHS Secretary, has been a vocal critic of mRNA vaccine technology and previously canceled roughly $500 million in mRNA vaccine research contracts.
The Arguments
Left argues
mRNA vaccines can be manufactured far faster than egg-based methods, which could be decisive in a pandemic flu scenario requiring rapid mass production of an updated vaccine.
Right counters
Speed of production is irrelevant if the underlying efficacy data, especially for the most vulnerable elderly population, remains unconfirmed pending a post-marketing study.
Right argues
The FDA's initial refusal to even review Moderna's application, followed by a reversal after negotiation, raises legitimate questions about whether the agency's comparator-trial standards are being applied consistently or bent under pressure.
Left counters
The reversal reflects normal regulatory back-and-forth—Moderna adjusted its application to address the FDA's concerns, and the process ultimately led to a unanimous advisory committee endorsement based on the science.
Left argues
The independent vaccine advisory committee's unanimous vote in favor of approval for both age groups shows that rigorous scientific review, not political ideology, determined the outcome despite Kennedy's hostility toward mRNA technology.
Right counters
A unanimous advisory vote doesn't erase the fact that the accelerated approval for those 65 and older is contingent on a future study, meaning the science on the most at-risk group is still incomplete.
Right argues
Secretary Kennedy's push to redirect funding toward diversified, established vaccine platforms reflects a reasonable policy goal of not over-relying on a single technology, especially given past controversies like Moderna's alleged withholding of data during its bivalent booster review.
Left counters
Cancelling nearly $500 million in mRNA research contracts based on ideological skepticism undermines the platform that experts say offers the fastest pandemic response capability, potentially leaving the country less prepared for a future flu emergency.
Left argues
The approval represents a check on Kennedy's broader anti-mRNA campaign, demonstrating that HHS leadership's skepticism did not ultimately override independent scientific and regulatory processes.
Right counters
Calling this a 'rebuke' overstates the case when the approval itself was delayed, restructured, and still requires further confirmatory data—hardly a clean vindication of the technology.
Challenge Questions
These questions target genuine internal contradictions — meant to provoke honest reflection.
Right asks Left
“If the accelerated approval for adults 65 and older is explicitly contingent on a future postmarket study to confirm effectiveness, how can this be framed as a clear scientific vindication of mRNA technology rather than a conditional, still-unproven approval?”
Left asks Right
“If Secretary Kennedy's concerns about mRNA technology are based on rigorous safety and efficacy standards, why did the FDA's own independent advisory committee unanimously conclude the benefits outweighed the risks for both age groups?”
Outlier Report
Left Fringe
Anti-vaccine wellness commentators occasionally aligned with the left, such as some RFK-sympathetic independents or figures like Naomi Wolf, represent a small fringe (under 5%) skeptical of mRNA technology broadly.
Right Fringe
Figures like Alex Berenson, Steve Kirsch, and some segments of the MAGA base who echo RFK Jr.'s strongest claims that mRNA vaccines are 'the deadliest vaccine ever made' represent a vocal but limited fringe, likely 20-25% of the right, while most Republicans and conservatives take a more moderate 'skeptical but not opposed' stance.
Noise Assessment
High amplification exists in this story due to RFK Jr.'s celebrity status and controversial rhetoric, but underlying public opinion on vaccine science and FDA authority remains more moderate and consensus-driven than the loudest voices suggest.
Sources (10)
The Food and Drug Administration has approved the first messenger RNA-based vaccine for seasonal flu, after rejecting it earlier this year.
The U.S. Food and Drug Administration has approved a new seasonal flu vaccine from Moderna that uses mRNA technology, the drugmaker announced.
The Food and Drug Administration has approved a new kind of flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic, manufacturer Moderna said.
The shot, named mFlusiva, is intended for adults age 50 or older.
The Food and Drug Administration (FDA) late Wednesday approved the nation’s first mRNA flu vaccine, manufactured by drugmaker Moderna.  The agency approved the shot for two separate age groups: people who are 50 to 64 years old, and people 65 years and older. Moderna said it will conduct a postmarket clinical trial to confirm the…
The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season. Moderna, the vaccine's maker
Flu season is inevitable. This year’s could be better.
This story appeared in Today, Explained, a daily newsletter that helps you understand the most compelling news and stories of the day. Subscribe here. The Food and Drug Administration approved Moderna’s mRNA flu vaccine this week — a major public health breakthrough for an administration that’s been troublingly down on vaccines.  The flu is a gigantic and costly […]